Connect Biopharma Holdings Ltd ADR (CNTB)

$2.57 +0.08 (3.21%)
Market Cap 139.20M
Revenue (ttm) 26.03M
Net Income (ttm) -15.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60.05%
Debt to Equity Ratio 0.00
Volume 1,466,100
Avg Vol 108,306
Day's Range N/A - N/A
Shares Out 55.90M
Stochastic %K 93%
Beta -0.14
Analysts Strong Sell
Price Target $7.62

Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquarte...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1040
Address:
3580 CARMEL MOUNTAIN ROAD, SUITE 200, San Diego, United States
StockScanners
StockScanners Nov. 19 at 3:55 AM
$CNTB reached 2.60
0 · Reply
JPecton
JPecton Nov. 18 at 8:01 PM
$CNTB Nice set up
0 · Reply
mikeywo
mikeywo Nov. 18 at 5:38 PM
$CNTB 3$ is next and then we take off in 2026 after hopefully strong data in Q2 26.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 18 at 5:37 PM
$CNTB has jumped 8% higher to 0% (~925Kv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
TheWings977
TheWings977 Nov. 18 at 2:37 PM
$CNTB BioFortune selling 500k shares. Sheesh
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 12:19 AM
Top Gainers PT2 $TOI $NOMA $CNTB $PGEN $OMER
0 · Reply
jacksonjohn750
jacksonjohn750 Nov. 17 at 11:00 PM
$CNTB offering i s next
1 · Reply
RunnerSignals
RunnerSignals Nov. 17 at 9:21 PM
Movers in Motion 🚀 $VSTM $IVVD $CNTB $ANRO $JKS are lighting up the tape today! Big spikes and heavy volume https://stocksrunner.com/news/2025-11-17-movers-and-shakers-leading-today-market-buzz
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 17 at 4:33 PM
$CNTB has reversed -4% lower to 11% (~1Mv) a few minutes ago, 11/21 options, follow for more volatility.
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Nov. 17 at 4:05 PM
$CNTB I was wondering the same. No news and this is day 2 popping
1 · Reply
Latest News on CNTB
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 6 days ago

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Nov 3, 2025, 9:36 PM EST - 15 days ago

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Sep 29, 2025, 9:00 AM EDT - 7 weeks ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 4, 2025, 8:00 AM EDT - 2 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Sep 3, 2025, 8:00 AM EDT - 2 months ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Aug 27, 2025, 9:00 AM EDT - 2 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 14, 2025, 8:00 AM EDT - 3 months ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 9:00 AM EDT - 3 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 22, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 21, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 18, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 17, 2025, 9:00 AM EDT - 4 months ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 13, 2025, 9:00 AM EDT - 5 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 28, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 20, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 14, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

May 13, 2025, 9:00 AM EDT - 6 months ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 24, 2025, 9:00 AM EDT - 7 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Apr 1, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 4:05 PM EDT - 8 months ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 31, 2025, 9:00 AM EDT - 8 months ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 28, 2025, 4:05 PM EDT - 8 months ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Present at Two Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 9 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Attovia Therapeutics Appoints Chief Financial Officer

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Attovia Therapeutics Appoints Chief Financial Officer

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 9, 2024, 3:55 PM EDT - 1 year ago

CNTB Stock Dips Amid Biotech Sector Volatility

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 6:03 PM EDT - 1 year ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Jun 12, 2024, 4:15 PM EDT - 1 year ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 22, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 1 year ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Feb 12, 2024, 4:30 PM EST - 1 year ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Dec 12, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Dec 11, 2023, 4:05 PM EST - 2 years ago

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Nov 21, 2023, 6:03 AM EST - 2 years ago

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Nov 21, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Nov 20, 2023, 4:41 PM EST - 2 years ago

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Sep 12, 2023, 4:15 PM EDT - 2 years ago

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Sep 12, 2023, 6:00 AM EDT - 2 years ago

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Participate in Upcoming September Investor Conferences

Aug 24, 2023, 6:21 PM EDT - 2 years ago

Connect Biopharma to Participate in Upcoming September Investor Conferences

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Apr 11, 2023, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Mar 18, 2023, 2:40 PM EDT - 2 years ago

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

StockScanners
StockScanners Nov. 19 at 3:55 AM
$CNTB reached 2.60
0 · Reply
JPecton
JPecton Nov. 18 at 8:01 PM
$CNTB Nice set up
0 · Reply
mikeywo
mikeywo Nov. 18 at 5:38 PM
$CNTB 3$ is next and then we take off in 2026 after hopefully strong data in Q2 26.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 18 at 5:37 PM
$CNTB has jumped 8% higher to 0% (~925Kv) a moment ago, 11/21 options, follow for more volatility.
0 · Reply
TheWings977
TheWings977 Nov. 18 at 2:37 PM
$CNTB BioFortune selling 500k shares. Sheesh
0 · Reply
topstockalerts
topstockalerts Nov. 18 at 12:19 AM
Top Gainers PT2 $TOI $NOMA $CNTB $PGEN $OMER
0 · Reply
jacksonjohn750
jacksonjohn750 Nov. 17 at 11:00 PM
$CNTB offering i s next
1 · Reply
RunnerSignals
RunnerSignals Nov. 17 at 9:21 PM
Movers in Motion 🚀 $VSTM $IVVD $CNTB $ANRO $JKS are lighting up the tape today! Big spikes and heavy volume https://stocksrunner.com/news/2025-11-17-movers-and-shakers-leading-today-market-buzz
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 17 at 4:33 PM
$CNTB has reversed -4% lower to 11% (~1Mv) a few minutes ago, 11/21 options, follow for more volatility.
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Nov. 17 at 4:05 PM
$CNTB I was wondering the same. No news and this is day 2 popping
1 · Reply
TheWings977
TheWings977 Nov. 17 at 3:53 PM
$CNTB any real reason as to why this is popping off?
0 · Reply
TheWings977
TheWings977 Nov. 17 at 3:31 PM
$CNTB 👀
0 · Reply
ImATraderBro
ImATraderBro Nov. 17 at 4:31 AM
$CNTB 👀
0 · Reply
topstockalerts
topstockalerts Nov. 15 at 12:05 PM
Top Gainers PT2 $TOI $NOMA $CNTB $PGEN $OMER
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:00 AM
$CNTB keep watch if this holds above 1.80
0 · Reply
topstockalerts
topstockalerts Nov. 15 at 12:18 AM
Top Gainers PT2 $TOI $NOMA $CNTB $PGEN $OMER
0 · Reply
IntraTrades
IntraTrades Nov. 14 at 10:41 PM
$CYCU 54.15% $CMCT 40.15% $SONN 33.63% $CYPH 33.50% $CNTB 31.68%
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 9:55 PM
Top Gainers PT2 $TOI $NOMA $CNTB $PGEN $OMER
0 · Reply
topstockalerts
topstockalerts Nov. 14 at 9:14 PM
Top Gainers PT2 $TOI $NOMA $CNTB $OMER $SRRK
0 · Reply
BioCurious1
BioCurious1 Nov. 14 at 6:12 PM
$CNTB https://www.marketbeat.com/instant-alerts/connect-biopharmas-cntb-buy-rating-reiterated-at-btig-research-2025-11-13/
2 · Reply
CarpeDiem_
CarpeDiem_ Nov. 14 at 6:07 PM
$CNTB oh Barry
0 · Reply
TheWings977
TheWings977 Nov. 14 at 3:59 PM
$CNTB tf is going on here? 400k+ in volume is wild.
0 · Reply